JPH11501331A - 注射用キノロン製剤 - Google Patents
注射用キノロン製剤Info
- Publication number
- JPH11501331A JPH11501331A JP9523447A JP52344797A JPH11501331A JP H11501331 A JPH11501331 A JP H11501331A JP 9523447 A JP9523447 A JP 9523447A JP 52344797 A JP52344797 A JP 52344797A JP H11501331 A JPH11501331 A JP H11501331A
- Authority
- JP
- Japan
- Prior art keywords
- solution
- danofloxacin
- formulation
- added
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.細菌感染の治療に充分な量のダノフロキサシン又は薬剤学的に許容すること のできるその塩、及び(1)マグネシウム化合物、又は(2)亜鉛化合物の共溶 媒との混合物を含み、前記化合物及び前記共溶媒が注射部位における耐性の向上 に充分な量で存在する、宿主への注入に適した薬剤水溶液。 2.前記のマグネシウム化合物が、共溶媒と共に存在する、請求項1に記載の溶 液。 3.前記の共溶媒が、2−ピロリドン、プロピレングリコール、ポリエチレング リコール、及びN−メチル−ピロリドンの少なくとも1つであり、いずれの化合 物も、場合によりポリビニルピロリドンと一緒であることができる、請求項1又 は2に記載の溶液。 4.抗酸化剤を更に含む、請求項1、2、又は3のいずれか一項に記載の水溶液 。 5.抗酸化剤が、ナトリウムホルムアルデヒドスルホキシレートである、請求項 4に記載の溶液。 6.溶液のpHを約5〜約9.5に調整するための成分を更に含む、請求項1〜 5のいずれか一項に記載の溶液。 7.溶液のpHが約6.5〜約9.0である、請求項1〜6のいずれか一項に記 載の溶液。 8.細菌感染の治療に充分な量のダノフロキサシン又は薬剤学的に許容すること のできるその塩、及び(1)マグネシウム化合物、又は(2)亜鉛化合物の共溶 媒との混合物を含み、前記化合物及び前記共溶媒が注射部位の耐性の向上に充分 な量で存在する薬剤水溶液を、宿主に注入することを含む、宿主における細菌感 染の治療方法。 9.前記宿主が畜牛であり、前記治療を皮下注射によって実施する、請求項8に 記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US905295P | 1995-12-21 | 1995-12-21 | |
US60/009,052 | 1995-12-21 | ||
PCT/IB1996/001217 WO1997023217A1 (en) | 1995-12-21 | 1996-11-13 | Injectable quinolone formulations |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH11501331A true JPH11501331A (ja) | 1999-02-02 |
JP3416145B2 JP3416145B2 (ja) | 2003-06-16 |
Family
ID=21735307
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP52344797A Expired - Lifetime JP3416145B2 (ja) | 1995-12-21 | 1996-11-13 | 注射用キノロン製剤 |
Country Status (42)
Country | Link |
---|---|
US (1) | US5811130A (ja) |
EP (1) | EP0868183B1 (ja) |
JP (1) | JP3416145B2 (ja) |
KR (1) | KR100402570B1 (ja) |
CN (1) | CN1104899C (ja) |
AP (1) | AP706A (ja) |
AR (1) | AR005147A1 (ja) |
AT (1) | ATE212551T1 (ja) |
AU (1) | AU709474B2 (ja) |
BG (1) | BG63933B1 (ja) |
BR (1) | BR9612230A (ja) |
CA (1) | CA2239352C (ja) |
CO (1) | CO4480098A1 (ja) |
CZ (1) | CZ293747B6 (ja) |
DE (1) | DE69618987T2 (ja) |
DK (1) | DK0868183T3 (ja) |
DZ (1) | DZ2146A1 (ja) |
EG (1) | EG24071A (ja) |
ES (1) | ES2167609T3 (ja) |
GT (1) | GT199600098A (ja) |
HR (1) | HRP960607B1 (ja) |
HU (1) | HU227918B1 (ja) |
IL (1) | IL124454A (ja) |
IS (1) | IS2010B (ja) |
MA (1) | MA24035A1 (ja) |
MX (1) | MX9805026A (ja) |
MY (1) | MY117109A (ja) |
NO (1) | NO315734B1 (ja) |
NZ (2) | NZ320545A (ja) |
OA (1) | OA10697A (ja) |
PE (1) | PE25798A1 (ja) |
PL (1) | PL186795B1 (ja) |
PT (1) | PT868183E (ja) |
RS (1) | RS49523B (ja) |
RU (1) | RU2141827C1 (ja) |
SI (1) | SI0868183T1 (ja) |
SK (1) | SK284412B6 (ja) |
TN (1) | TNSN96163A1 (ja) |
TW (1) | TW449475B (ja) |
UA (1) | UA56151C2 (ja) |
WO (1) | WO1997023217A1 (ja) |
ZA (1) | ZA9610780B (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006004028A1 (ja) * | 2004-07-02 | 2006-01-12 | Daiichi Pharmaceutical Co., Ltd. | キノロン含有医薬組成物 |
JP2013082736A (ja) * | 2005-05-18 | 2013-05-09 | Mpex Pharmaceuticals Inc | エアロゾル化フルオロキノロンおよびその使用 |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ID21415A (id) * | 1997-12-05 | 1999-06-10 | Upjohn Co | Senyawa-senyawa antibiotik magnesium quinolon |
US6017948A (en) * | 1998-10-30 | 2000-01-25 | Supergen, Inc. | Water-miscible pharmaceutical compositions |
DE19937116A1 (de) * | 1999-08-06 | 2001-02-08 | Bayer Ag | Moxifloxacin Kochsalzformulierung |
DE19937115A1 (de) | 1999-08-06 | 2001-02-08 | Bayer Ag | Wäßrige Arzneimittelformulierung von Moxifloxacin oder Salzen davon |
US20030153585A1 (en) * | 2000-01-13 | 2003-08-14 | Sven-Alexander Schreder | Pharmaceutical preparations containing 2-pyrrolidone as the dissolving intermediary |
US8637077B2 (en) | 2000-12-28 | 2014-01-28 | Takeda Pharmaceutical Company Limited | Sustained-release preparation |
CA2488526A1 (en) * | 2002-06-26 | 2004-01-08 | Pharmacia Corporation | Stable liquid parenteral parecoxib formulation |
US8524734B2 (en) | 2005-05-18 | 2013-09-03 | Mpex Pharmaceuticals, Inc. | Aerosolized fluoroquinolones and uses thereof |
FR2896416B1 (fr) | 2006-01-24 | 2010-08-13 | Vetoquinol | Composition anti-infectieuse comprenant un compose de type pyrido (3,2,1-ij)-benzoxadiazine |
CA2641827A1 (en) * | 2006-02-10 | 2007-08-16 | Pari Pharma Gmbh | Nebulised antibiotics for inhalation therapy |
US20070197548A1 (en) * | 2006-02-17 | 2007-08-23 | Murthy Yerramilli V S | Fluoroquinolone compositions |
DE102006010643A1 (de) * | 2006-03-08 | 2007-09-13 | Bayer Healthcare Aktiengesellschaft | Arzneimittel enthaltend Fluorchinolone |
DE102006010642A1 (de) * | 2006-03-08 | 2007-09-27 | Bayer Healthcare Aktiengesellschaft | Arzneimittelformulierungen, enthaltend Fluorchinolone |
MX2007009796A (es) | 2007-08-14 | 2009-02-25 | Cell Therapy And Technology S | Gel conteniendo pirfenidona. |
PL2344129T3 (pl) | 2008-10-07 | 2018-07-31 | Horizon Orphan Llc | Formulacje fluorochinolonu w aerozolu dla poprawy właściwości farmakokinetycznych |
EP2346509B1 (en) | 2008-10-07 | 2020-05-13 | Horizon Orphan LLC | Inhalation of levofloxacin for reducing lung inflammation |
AU2010289326B2 (en) | 2009-09-04 | 2015-09-24 | Horizon Therapeutics U.S. Holding Llc | Use of aerosolized levofloxacin for treating cystic fibrosis |
MX2011007675A (es) | 2011-07-19 | 2012-07-11 | Cell Therapy And Technology S A De C V | Procedimiento para la fabricacion de una composicion farmaceutica en forma de tabletas de liberacion prolongada conteniendo pirfenidona y su aplicacion en la regresion de la insuficiencia renal cronica, contractura capsular mamaria y fibrosis hepatica humanas. |
MX346763B (es) | 2012-03-28 | 2017-03-31 | Cell Therapy And Tech S A De C V | Composición tópica semisólida conteniendo pirfenidona y dialil óxido de disulfuro modificado (odd-m) para eliminar o prevenir el acné. |
MX356551B (es) | 2012-08-23 | 2018-06-04 | Grupo Medifarma S A De C V Star | Composición antiséptica, antiseborreica y exfoliante para eliminar o prevenir el acné. |
EP3305295A4 (en) | 2015-06-02 | 2019-02-20 | Kyorin Pharmaceutical Co., Ltd. | AQUEOUS MEDICINE |
EP3305294A4 (en) | 2015-06-02 | 2019-02-20 | Kyorin Pharmaceutical Co., Ltd. | AQUEOUS MEDICINE |
US10406149B2 (en) | 2015-06-02 | 2019-09-10 | Kyorin Pharmaceutical Co., Ltd. | Aqueous liquid formulation |
AU2018217931B2 (en) * | 2017-02-13 | 2023-04-13 | Elanco Animal Health Gmbh | Liquid composition containing pradofloxacin |
MX366086B (es) | 2017-08-15 | 2019-06-27 | Cell Therapy And Tech S A De C V | Composicion topica semisolida conteniendo un agente antimicrobiano y pirfenidona para el tratamiento de daños cronicos de la piel. |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3517709A1 (de) * | 1985-01-05 | 1986-07-10 | Bayer Ag | Basische zubereitungen von chinoloncarbonsaeuren |
JPS63188626A (ja) * | 1987-01-30 | 1988-08-04 | Dainippon Pharmaceut Co Ltd | ピリドンカルボン酸の可溶化方法 |
DE3902079A1 (de) * | 1988-04-15 | 1989-10-26 | Bayer Ag | I.m. injektionsformen von gyrase-inhibitoren |
JP3153549B2 (ja) * | 1989-12-29 | 2001-04-09 | アボツト・ラボラトリーズ | キノロンカルボン酸―金属イオン―酸錯体 |
US5084276A (en) * | 1990-01-05 | 1992-01-28 | Abbott Laboratories | Quinolone carboxylic acid compositions with polymeric additive to reduce vein irritation |
ATE108649T1 (de) * | 1990-02-14 | 1994-08-15 | Takeda Chemical Industries Ltd | Brausemischung, deren herstellung sowie verwendung. |
FR2665635A1 (fr) * | 1990-08-10 | 1992-02-14 | Merck Sharp & Dohme | Composition pharmaceutique fluide a base d'un complexe metallique et son procede de preparation. |
US5082863A (en) * | 1990-08-29 | 1992-01-21 | Schering Corporation | Pharmaceutical composition of florfenicol |
US5235054A (en) * | 1992-07-15 | 1993-08-10 | Pfizer Inc. | 3-carboxaldehyde substituted quinolines and naphthyridines |
JPH0782141A (ja) * | 1993-09-17 | 1995-03-28 | Tanabe Seiyaku Co Ltd | 動物用注射剤 |
-
1996
- 1996-11-13 HU HU9903726A patent/HU227918B1/hu unknown
- 1996-11-13 IL IL12445496A patent/IL124454A/xx not_active IP Right Cessation
- 1996-11-13 CN CN96199249A patent/CN1104899C/zh not_active Expired - Lifetime
- 1996-11-13 NZ NZ320545A patent/NZ320545A/xx not_active IP Right Cessation
- 1996-11-13 JP JP52344797A patent/JP3416145B2/ja not_active Expired - Lifetime
- 1996-11-13 DK DK96935251T patent/DK0868183T3/da active
- 1996-11-13 NZ NZ501160A patent/NZ501160A/en not_active IP Right Cessation
- 1996-11-13 RU RU98111831A patent/RU2141827C1/ru active
- 1996-11-13 AT AT96935251T patent/ATE212551T1/de active
- 1996-11-13 BR BR9612230A patent/BR9612230A/pt active IP Right Grant
- 1996-11-13 SK SK807-98A patent/SK284412B6/sk not_active IP Right Cessation
- 1996-11-13 PL PL96328001A patent/PL186795B1/pl unknown
- 1996-11-13 KR KR10-1998-0704719A patent/KR100402570B1/ko not_active IP Right Cessation
- 1996-11-13 SI SI9630422T patent/SI0868183T1/xx unknown
- 1996-11-13 AU AU73289/96A patent/AU709474B2/en not_active Expired
- 1996-11-13 DE DE69618987T patent/DE69618987T2/de not_active Expired - Lifetime
- 1996-11-13 ES ES96935251T patent/ES2167609T3/es not_active Expired - Lifetime
- 1996-11-13 EP EP96935251A patent/EP0868183B1/en not_active Expired - Lifetime
- 1996-11-13 CZ CZ19981930A patent/CZ293747B6/cs not_active IP Right Cessation
- 1996-11-13 UA UA98063226A patent/UA56151C2/uk unknown
- 1996-11-13 WO PCT/IB1996/001217 patent/WO1997023217A1/en active IP Right Grant
- 1996-11-13 PT PT96935251T patent/PT868183E/pt unknown
- 1996-11-13 CA CA002239352A patent/CA2239352C/en not_active Expired - Lifetime
- 1996-11-15 TW TW085114021A patent/TW449475B/zh not_active IP Right Cessation
- 1996-12-10 PE PE1996000892A patent/PE25798A1/es not_active Application Discontinuation
- 1996-12-17 EG EG113496A patent/EG24071A/xx active
- 1996-12-18 MA MA24427A patent/MA24035A1/fr unknown
- 1996-12-18 TN TNTNSN96163A patent/TNSN96163A1/fr unknown
- 1996-12-18 DZ DZ960191A patent/DZ2146A1/fr active
- 1996-12-19 AP APAP/P/1996/000898A patent/AP706A/en active
- 1996-12-19 GT GT199600098A patent/GT199600098A/es unknown
- 1996-12-19 AR ARP960105774A patent/AR005147A1/es active IP Right Grant
- 1996-12-19 HR HR960607A patent/HRP960607B1/xx not_active IP Right Cessation
- 1996-12-19 US US08/769,809 patent/US5811130A/en not_active Expired - Lifetime
- 1996-12-20 MY MYPI96005411A patent/MY117109A/en unknown
- 1996-12-20 CO CO96066993A patent/CO4480098A1/es unknown
- 1996-12-20 RS YU69096A patent/RS49523B/sr unknown
- 1996-12-20 ZA ZA9610780A patent/ZA9610780B/xx unknown
-
1998
- 1998-05-25 IS IS4755A patent/IS2010B/is unknown
- 1998-06-12 OA OA9800082A patent/OA10697A/en unknown
- 1998-06-15 BG BG102542A patent/BG63933B1/bg unknown
- 1998-06-19 NO NO19982842A patent/NO315734B1/no not_active IP Right Cessation
- 1998-06-19 MX MX9805026A patent/MX9805026A/es unknown
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006004028A1 (ja) * | 2004-07-02 | 2006-01-12 | Daiichi Pharmaceutical Co., Ltd. | キノロン含有医薬組成物 |
JPWO2006004028A1 (ja) * | 2004-07-02 | 2008-04-24 | 第一製薬株式会社 | キノロン含有医薬組成物 |
JP2013082736A (ja) * | 2005-05-18 | 2013-05-09 | Mpex Pharmaceuticals Inc | エアロゾル化フルオロキノロンおよびその使用 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH11501331A (ja) | 注射用キノロン製剤 | |
US6548079B1 (en) | Moxifloxacin formulation containing common salt | |
US20090246277A9 (en) | Controlled release system | |
KR20040085196A (ko) | 항신생물제, 특히 테모졸로마이드의 약제학적 제형, 이의제조 및 사용 방법 | |
US4772460A (en) | Method of reducing the swelling or pain associated with antibiotics compositions | |
US6288080B1 (en) | Magnesium quinolone antibiotics | |
US7094414B2 (en) | Famotidine injections | |
ES2373042T3 (es) | Solución de metilfenidato y procedimientos de administración y producción asociados. | |
US5084276A (en) | Quinolone carboxylic acid compositions with polymeric additive to reduce vein irritation | |
EP0365363B1 (en) | Parenteral formulations of 1-diphenylmethyl-4-[(2-(4-methylphenyl)-5-methyl-1H-imidazol-4-yl)methyl]piperazine | |
US5753636A (en) | Injection solution for intramuscular and subcutaneous administration to animals | |
US5063220A (en) | Parenteral formulations of 1-diphenylmethyl-4-((2-(4-methylphenyl)-5-methyl-1H-imidazol-4-yl)methyl)piperazine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080404 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090404 Year of fee payment: 6 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090404 Year of fee payment: 6 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100404 Year of fee payment: 7 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100404 Year of fee payment: 7 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110404 Year of fee payment: 8 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130404 Year of fee payment: 10 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140404 Year of fee payment: 11 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
EXPY | Cancellation because of completion of term |